<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37515691</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Multiplex real-time PCR FilmArray performance in the diagnosis of meningoencephalitis: lights and shadows.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>172</EndPage><MedlinePgn>165-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-023-02076-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We aimed to evaluate the performance of the FilmArray (FA) meningitis/encephalitis (ME) panel. Secondarily, we analyzed the false positive (FP) and false negative (FN) results, as well as the predictive values of the technique, regarding the cerebrospinal fluid (CSF) characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">FA is a multiplex real-time PCR detecting 14 of the most common ME pathogens in CSF. All FA performed at our hospital (2018-2022) were retrospectively reviewed. FA was compared to conventional techniques and its performance was assessed based on the final diagnosis of the episode.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">FA was performed in 313 patients with suspicion of ME. Most patients had altered mental status (65.2%) and fever (61%). Regarding CSF characteristics, 49.8% and 53.7% presented high CSF proteins and pleocytosis, respectively. There were 84 (26.8%) positive FA results, mainly for HSV-1 (10.9%), VZV (5.1%), Enterovirus (2.6%), and S. pneumoniae (1.9%). In the 136 cases where both FA and routine methods were performed, there was a 25.7% lack of agreement. We identified 6.6% FN results, but 28.6% FP, mainly due to HSV-1. This resulted in a high negative predictive value (NPV) of 93.4%, but a positive predictive value (PPV) of 73%. Remarkably, PPV as low as 36.9%, and 70.2%, were found in cases without pleocytosis, or lack of high CSF protein levels, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">FA was associated with high NPV, but frequent FP results and low PPV, particularly for HSV-1, and especially in patients without high CSF protein levels or pleocytosis.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>López</LastName><ForeName>Néstor</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cuesta</LastName><ForeName>Genoveva</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Vega</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Cabueñes, Gijón, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>Enric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chumbita</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casals-Pascual</LastName><ForeName>Climent</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morata</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergara</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodro</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez</LastName><ForeName>Jose Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mensa</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Vidal</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>María Ángeles</ForeName><Initials>MÁ</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERINF, CIBER Infectious Diseases, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puerta-Alcalde</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital Clínic-IDIBAPS, Barcelona, Spain. pedro.puerta84@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Barcelona (UB), Barcelona, Spain. pedro.puerta84@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JR20/00012</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country /></Grant><Grant><GrantID>PI21/00498</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country /></Grant><Grant><GrantID>ICI21/00103</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008581" MajorTopicYN="Y">Meningitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="Y">Encephalitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="Y">Meningoencephalitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060885" MajorTopicYN="N">Multiplex Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BioFire</Keyword><Keyword MajorTopicYN="N">Encephalitis</Keyword><Keyword MajorTopicYN="N">Meningitis</Keyword><Keyword MajorTopicYN="N">Meningoencephalitis</Keyword><Keyword MajorTopicYN="N">Multiplex real-time PCR</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. CG-V has received honoraria for talks on behalf of Gilead Science, Merck Sharp and Dohme, Pfizer, Jannsen, Novartis, Lilly and a grant support from Gilead Science and Merck Sharp and Dohme. AS has received honoraria for lectures and advisory boards from Pfizer, Merck Sharp and Dohme, Shionogi, Angelini, Menarini, and Gilead Sciences. AS has received grants from Pfizer and Gilead Sciences. P.P.-A. has received honoraria for talks on behalf of Merck Sharp and Dohme, Lilly, ViiV Healthcare and Gilead Science. P.P.-A. has participated in advisory boards for Gilead Science.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37515691</ArticleId><ArticleId IdType="pmc">PMC10810907</ArticleId><ArticleId IdType="doi">10.1007/s15010-023-02076-x</ArticleId><ArticleId IdType="pii">10.1007/s15010-023-02076-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meningitis—Level 3 cause | Institute for Health Metrics and Evaluation. https://www.healthdata.org/results/gbd_summaries/2019/meningitis-level-3-cause. Retrieved 6 March 2023.</Citation></Reference><Reference><Citation>Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317–328. doi: 10.1016/S1473-3099(10)70048-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70048-7</ArticleId><ArticleId IdType="pubmed">20417414</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsett M, Liang SY. Diagnosis and treatment of central nervous system infections in the emergency department. Emerg Med Clin North Am. 2016;34:917–942. doi: 10.1016/j.emc.2016.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.emc.2016.06.013</ArticleId><ArticleId IdType="pmc">PMC5082707</ArticleId><ArticleId IdType="pubmed">27741995</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer MC, Tunkel AR, Van De Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467–492. doi: 10.1128/CMR.00070-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00070-09</ArticleId><ArticleId IdType="pmc">PMC2901656</ArticleId><ArticleId IdType="pubmed">20610819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cailleaux M, Pilmis B, Mizrahi A, Lourtet-Hascoet J, Van JCN, Alix L, Couzigou C, Vidal B, Tattevin P, Le Monnier A. Impact of a multiplex PCR assay (FilmArray®) on the management of patients with suspected central nervous system infections. Eur J Clin Microbiol Infect Dis. 2020;39:293–297. doi: 10.1007/s10096-019-03724-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-019-03724-7</ArticleId><ArticleId IdType="pubmed">31720944</ArticleId></ArticleIdList></Reference><Reference><Citation>Biofire Diagnostics. 2020. BioFire FilmArray Meningitis/Encephalitis Panel (ME) | BioFire Diagnostics. https://www.biofiredx.com/products/the-filmarray-panels/filmarrayme/. Retrieved 6 March 2023.</Citation></Reference><Reference><Citation>Tansarli GS, Chapin KC. Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:281–290. doi: 10.1016/j.cmi.2019.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.11.016</ArticleId><ArticleId IdType="pubmed">31760115</ArticleId></ArticleIdList></Reference><Reference><Citation>Trujillo-G Omez J, Tsokani S, Arango-Ferreira C, Atehort Ua-Mu~ S, Jos E Jimenez-Villegas M, Serrano-Tabares C, Veroniki A-A, Florez ID. Biofire FilmArray Meningitis/Encephalitis panel for the aetiological diagnosis of central nervous system infections: A systematic review and diagnostic test accuracy meta-analysis. eClinicalMedicine. 2022;44:101275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851290</ArticleId><ArticleId IdType="pubmed">35198914</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffa MA, Bremmer DN, Carr D, Buchanan C, Shively NR, Elrufay R, Walsh TL. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. Antibiotics. 2020;9:282. doi: 10.3390/antibiotics9060282.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9060282</ArticleId><ArticleId IdType="pmc">PMC7344633</ArticleId><ArticleId IdType="pubmed">32466378</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JJ, Zandotti C, Baron S, Kandil C, Levy PY, Drancourt M, Raoult D, Ninove L. Point-of-care multiplexed diagnosis of meningitis using the FilmArray® ME panel technology. Eur J Clin Microbiol Infect Dis. 2020;39:1573–1580. doi: 10.1007/s10096-020-03859-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03859-y</ArticleId><ArticleId IdType="pubmed">32358740</ArticleId></ArticleIdList></Reference><Reference><Citation>Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, Lephart P, Salimnia H, Schreckenberger PC, DesJarlais S, Reed SL, Chapin KC, LeBlanc L, Johnson JK, Soliven NL, Carroll KC, Miller JA, Bard JD, Mestas J, Bankowski M, Enomoto T, Hemmert AC, Bourzac KM. Multicenter evaluation of biofire filmarray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol. 2016;54:2251–2261. doi: 10.1128/JCM.00730-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00730-16</ArticleId><ArticleId IdType="pmc">PMC5005480</ArticleId><ArticleId IdType="pubmed">27335149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindström J, Elfving K, Lindh M, Westin J, Studahl M. Assessment of the FilmArray ME panel in 4199 consecutively tested cerebrospinal fluid samples. Clin Microbiol Infect. 2022;28:79–84. doi: 10.1016/j.cmi.2021.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.017</ArticleId><ArticleId IdType="pubmed">34015534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson KE, Slechta ES, Killpack JA, Heyrend C, Lunt T, Daly JA, Hemmert AC, Blaschke AJ. preclinical assessment of a fully automated multiplex PCR panel for detection of central nervous system pathogens. J Clin Microbiol. 2016;54:785–787. doi: 10.1128/JCM.02850-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02850-15</ArticleId><ArticleId IdType="pmc">PMC4767945</ArticleId><ArticleId IdType="pubmed">26719436</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesman RM, Strasburg AP, Heitman AK, Theel ES, Patel R, Binnicker MJ. Evaluation of a commercial multiplex molecular panel for diagnosis of infectious meningitis and encephalitis. J Clin Microbiol. 2018;56:e01927–e2017. doi: 10.1128/JCM.01927-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01927-17</ArticleId><ArticleId IdType="pmc">PMC5869843</ArticleId><ArticleId IdType="pubmed">29436421</ArticleId></ArticleIdList></Reference><Reference><Citation>Radmard S, Reid S, Ciryam P, Boubour A, Ho N, Zucker J, Sayre D, Greendyke WG, Miko BA, Pereira MR, Whittier S, Green DA, Thakur KT. Clinical utilization of the filmarray meningitis/encephalitis (ME) multiplex polymerase chain reaction (PCR) assay. Front Neurol. 2019;10:281. doi: 10.3389/fneur.2019.00281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00281</ArticleId><ArticleId IdType="pmc">PMC6443843</ArticleId><ArticleId IdType="pubmed">30972012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronska E, Kalmusova J, Dzupova O, Maresova V, Kriz P, Benes J. Dynamics of PCR-based diagnosis in patients with invasive meningococcal disease. Clin Microbiol Infect. 2006;12:137–141. doi: 10.1111/j.1469-0691.2005.01327.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2005.01327.x</ArticleId><ArticleId IdType="pubmed">16441451</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth R, Murthy PSR, Sistla S, Subramanian M, Tamilarasu K. Rapid and accurate diagnosis of acute pyogenic meningitis due to Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis using a multiplex PCR assay. J Clin Diagnostic Res. 2017;11:FC01–FC04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5713747</ArticleId><ArticleId IdType="pubmed">29207725</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovich K, Wingler MJB, Stover KR, Barber KE, Wagner JL, Cretella DA. Analysis of the clinical impact of the BioFire FilmArray meningitis encephalitis panel on antimicrobial use and duration of therapy at an academic medical center. Diseases. 2022;10:110. doi: 10.3390/diseases10040110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases10040110</ArticleId><ArticleId IdType="pmc">PMC9680255</ArticleId><ArticleId IdType="pubmed">36412604</ArticleId></ArticleIdList></Reference><Reference><Citation>DiDIodato G, Bradbury N. Cerebrospinal fluid analysis with the biofire filmarray meningitis/ encephalitis molecular panel reduces length of hospital stay in patients with suspected central nervous system infections. Open Forum Infect Dis. 2019;6:ofz119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483125</ArticleId><ArticleId IdType="pubmed">31041338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>